Sharemaestro Newsreel

ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx

SueWallSt has initiated an investigation into potential securities law violations by Ardelyx (NASDAQ: ARDX) following a significant drop in its stock price. The company lowered its 2026 IBSRELA revenue guidance by up to $80 million and withdrew its long-term XPHOZAH revenue target, citing payer …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

Are Investors Undervaluing Tenet Healthcare (THC) Right Now?

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in …

Trinity Biotech secures $7m from Perceptive Advisors By Investing.com

Trinity Biotech (NASDAQ:TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, comprising $2.5 million in new debt and $4.5 million in capitalized interest. This funding will support the company's CGM+ continuous glucose monitoring platform, Trinovium subsidiary, and diagnostics …

Form 8K Lifeward Ltd. For: 14 August By Investing.com

This article reports on the filing of Form 8K by Lifeward Ltd. on August 14th. It appears to be a standard financial news brief from Investing.com, providing basic information about the filing and its publication details.

Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Why Did Oscar Health (OSCR) Fall After Record Profit and a Guidance Hike?

Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net …

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

Trinity Biotech (NASDAQ: TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, and has regained compliance with Nasdaq's minimum bid price requirement. The investment, consisting of new debt funding and capitalized interest, aims to bolster liquidity for strategic …

Trinity Biotech Regains Nasdaq Compliance After 10 Days at $1 or More

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?

Shares of Tenet Healthcare (THC) have been strong performers lately, with the stock up 34.1% over the past month. The stock hit a new 52-week high of $270.57 in the previous session. Tenet has gained 34.4% since the start of the year compared to …

AMN Healthcare Services (NYSE:AMN) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

BioMarin Pharmaceutical (BMRN) is outperforming the Medical sector and its specific industry year-to-date, with a 15.3% return compared to the sector's 3%. The company holds a Zacks Rank #2 (Buy) due to improving analyst sentiment. Cardinal Health (CAH) is another medical stock showing strong …

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame

Brokers Offer Predictions for RAPP Q1 Earnings

Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

Q3 Earnings Estimate for AptarGroup Issued By Zacks Research

Q3 EPS Estimates for Journey Medical Cut by HC Wainwright

Sidoti Equities Analysts Raise Earnings Estimates for Kamada

Equities Analysts Set Expectations for TCRX FY2026 Earnings

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is brief and does not contain additional details within the provided content. It is published by Investing.com, a financial markets news platform.

Insider Spends US$141k Buying More Shares In Embecta

Embecta's President, Devdatt Kurdikar, recently purchased US$141k worth of company stock at US$4.70 per share, increasing his holding by 3.9%. This is the largest insider purchase in the last year, suggesting optimism for the company's future, despite the overall insider ownership being relatively low …

Embecta Corp. SVP Elguicze purchases $93,360 in common stock

Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, recently purchased 20,000 shares of the company's common stock for $93,360. This insider purchase comes after a significant stock decline but a recent rebound, with the company trading at a low P/E ratio. The purchase …

Sirenia Capital (HELP) reports 3.03M-share Cybin stake including warrant shares

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 3,029,500 Common Shares in Cybin Inc., which includes 969,500 shares issuable upon the exercise of warrants. This stake represents 4.8% of Cybin's outstanding Common Shares, based on 61,984,078 shares as of …

HC Wainwright Has Bearish Estimate for DTIL Q3 Earnings

Delcath Systems updates bylaws to designate Delaware courts as exclusive forum

Delcath Systems, Inc. (NASDAQ:DCTH) has amended its bylaws to designate Delaware courts as the exclusive forum for internal corporate claims and federal district courts for claims under the Securities Act of 1933. This decision follows a recommendation from its Nominating and Corporate Governance Committee. …

Form 8K Delcath Systems Inc For: 14 August By Investing.com

This article announces the filing of a Form 8K by Delcath Systems Inc. on August 14th. It is a brief news item from Investing.com, providing basic information about the regulatory filing.

Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn

Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …

Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026

Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …

Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com

This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.